此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

使用 Willem™ 软件对高危心脏病患者 (WILLEM) 进行 AI 驱动的 ECG 分析 (WILLEM)

2026年11月3日 更新者:Idoven 1903 S.L.

使用 Willem™ 心脏病专家级人工智能软件评估高危心脏病患者的心电图数据。威廉 审判。

WILLEM is a multi-center, prospective and retrospective cohort study.

The study will assess the performance of a cloud-based and AI-powered ECG analysis platform, named Willem™, developed to detect arrhythmias and other abnormal cardiac patterns. The main questions it aims to answer are:

  1. A new AI-powered ECG analysis platform can automatice the classification and prediction of cardiac arrhythmic episodes at a cardiologist level.
  2. This AI-powered ECG analysis can delay or even avoid harmful therapies and severe cardiac adverse events such as sudden death.

The prerequisites for inclusion of patients will be the availability of at least one ECG record in raw data, along with patient clinical data and evolution data after more than 1-year follow-up.

Cardiac electrical signals from multiple medical devices will be collected by cardiology experts after obtaining the informed consent. Every cardiac electrical signal from every subject will be reviewed by a board-certified cardiologist to label the arrhythmias and patterns recorded in those tracings. In order to obtain tracings of relevant information, >95% of the subjects enrolled will have rhythm disorders or abnormal ECG's patterns at the time of enrollment.

研究概览

详细说明

The WILLEM study is an investigator-initiated, multicenter, observational trial aiming to validate a cloud-based AI-powered ECG analysis platform to early diagnose and predict the behavior of cardiac abnormalities and cardiac diseases from patients admitted to cardiovascular units. Model-derived diagnosis will be compared with cardiology expert's diagnosis in a test dataset. Clinical outcomes will be included to assess model prediction capabilities: sensitivity, specificity and accuracy. In this observational study, patients will be randomly divided into two groups: (1) a training group to design new methodologies and algorithms; and (2) a test group to evaluate performance of methodologies aiming to avoid overfitting.

Willem™ AI-powered ECG analysis platform supports the analysis of cardiac electrical signals ≥ 10 seconds onwards obtained from devices in-clinic (E.g., 12-lead ECG devices at hospitals or primary care, telemetries, monitors) and at-home or telemedicine interfaces (E.g., Holter devices, event recorders, 6, 3, 2, 1-lead ECG wearables, textile electrodes and patches for mobile cardiac telemetry).

研究类型

观察性的

注册 (估计的)

5342

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:José María Lillo, PhD
  • 邮箱:c@idoven.ai

学习地点

    • Provincie Groningen
      • Groningen、Provincie Groningen、荷兰、9713 GZ
        • 完全的
        • University Medical Center Groningen
    • Barcelona
      • Barcelona、Barcelona、西班牙、08950
        • 完全的
        • Hospital Sant Joan de Déu
    • Ciudad Real
      • Ciudad Real、Ciudad Real、西班牙、13005
        • 完全的
        • Hospital General Universitario de Ciudad Real
    • La Coruña
      • A Coruña、La Coruña、西班牙、15006
        • 完全的
        • Complejo Hospitalario Universitario A Coruña
    • Madrid
      • Madrid、Madrid、西班牙、28822
        • 完全的
        • Hospital Universitario del Henares
      • Madrid、Madrid、西班牙、28400
        • 完全的
        • Hospital Universitario General de Villalba
      • Madrid、Madrid、西班牙、28040
        • 完全的
        • Hospital Clínico San Carlos
      • Madrid、Madrid、西班牙、28222
        • 完全的
        • Hospital Universitario Puerta de Hierro
    • Murcia
      • Murcia、Murcia、西班牙、30120
        • 完全的
        • Hospital Virgen de Arrixaca
    • Navarre
      • Pamplona、Navarre、西班牙、31008
        • 招聘中
        • Clínica Universitaria Navarra
        • 接触:
          • Manuel García de Yébenes Castro, MD
        • 首席研究员:
          • Manuel García de Yébenes Castro
    • Santa Cruz de Tenerife
      • Santa Cruz de Tenerife、Santa Cruz de Tenerife、西班牙、38010
        • 完全的
        • Hospital Universitario Nuestra Señora de Candelaria
    • Valencia
      • Valencia、Valencia、西班牙、46026
        • 完全的
        • Hospital Universitario y Politécnico La Fe
    • Vizcaya
      • Bilbao、Vizcaya、西班牙、48013
        • 招聘中
        • Hospital Universitario de Basurto
        • 接触:
          • Alain García Olea, MD
        • 首席研究员:
          • Alain García Olea

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

4年 及以上 (孩子、成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients recorded with a mid to long-term ECG device according to guidelines. ECG data (ECG must have been recorded according to the technical standards for the safety and essential performance of medical electrical equipment defined in EN 60601-2-47:2015.): 12-lead ECGs including rest electrocardiograms, stress ECG Test (exercise Electrocardiogram or treadmill test), Holter devices, long-duration Holter devices, event recorders, insertable cardiac monitors, 6,3,2,1-lead ECG wearables, textile electrodes and patches, smartwatches, cardiac monitors, cardiac telemetries, hemodynamic and electrophysiology recording system (i.e., polygraphs), automatic external defibrillator (AED), semi-automatic defibrillator (DESA), home telemonitoring systems and other similar devices.

描述

Inclusion Criteria:

  • Patient presenting relevant cardiac arrhythmias and cardiac patterns (including supraventricular tachycardias, abnormal ECG patterns, ventricular tachycardias, ventricular fibrillation, pulseless electrical activity or asystole among others) that have been recorded with at least one short-term ECG medical device according to guidelines with ≥1 signal-channel.
  • Patient with suspected or diagnosed acute/chronic cardiac diseases (including patients with heart failure, patients with history of cardiac arrhythmias, patients with probable coronary artery diseases, patients with cardiomyopathies, patients with pacemakers or implantable cardioverter-defibrillators (ICD), patients with indication of pacemaker or ICD in current or short-term phase, patients participating in other interventional clinical investigation, patients with hemodynamic instability or acute coronary syndromes, pregnant patients, patients with cancer and chemotherapy, patients with life-expectancy lower than 24 months, patients with in or out-of-hospital cardiac arrest with ventricular fibrillation as first documented rhythm).
  • At least one ECG tracing that can be exported in raw data.
  • Signed informed consent. Patients unable to consent, it will be requested to an authorized relative.

Exclusion Criteria:

  • Unwillingness or inability to sign study written informed consent.
  • Unavailable or suboptimal quality of the electrocardiographic signal in raw data.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:RETROSPECTIVE

队列和干预

团体/队列
干预/治疗
Train group

Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record >10 sec in raw data will be used to design new methodologies and algorithms for cardiac patterns recognition.

ECG recording and processing by AI platform

Test group

Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record >10 sec in raw data will be used to evaluate performance of methodologies aiming to avoid overfitting. Every 10 patients included in Train group; a new patient is included in the test group.

ECG recording and processing by AI platform

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Detection of cardiac arrhythmias and cardiac patterns in the electrocardiographic signals
大体时间:real time to 7 minutes

Willem™ heart rhythm and cardiac pattern performance compared to standard manually performed cardiologist diagnosis.

real time to 7 minutes

次要结果测量

结果测量
措施说明
大体时间
Survival at follow-up
大体时间:1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)

Patients alive at the time of follow-up

1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
大体时间:1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)

MACCE rates defined as cardiovascular and cerebrovascular events during the follow up

1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)
Re-hospitalization
大体时间:1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)

Number of Re-hospitalizations during the follow up.

1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)
Change in quality of life
大体时间:1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)

European Quality of Life-5 Dimensions (EQ-5D) index an utility scores anchored at 0 for death and 1 for perfect health.

1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:María De La Parte, MD、Idoven 1903 S.L.

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年4月4日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2023年5月26日

首先提交符合 QC 标准的

2023年5月26日

首次发布 (实际的)

2023年6月6日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅